— If approved in the European Union, fruquintinib will be the first novel targeted therapy for metastatic colorectal cancer regardless…
Company to host virtual investor event on Friday, May 3, 2024, at 4:30pm EDT following presentation of results from the…
Decision by EMA follows recent judgment by the Court of Justice of the European Union regarding the organization of EMA’s…
The Company will host a conference call and webcast on Wednesday, May 8, 2024 at 8:00 a.m. ETNEW YORK, April…
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE26 APRIL 2024 at 11.15…
Planegg/Martinsried, April 26, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on…
Ad hoc announcement pursuant to Art. 53 LR Idorsia receives a positive opinion from the Committee for Medicinal Products for…
PALO ALTO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced the pricing of an…
SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage…
NOVATO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development…